Quantcast

Latest Bremelanotide Stories

2014-09-09 08:30:55

CRANBURY, N.J., Sept. 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2014. Fiscal Year Ended June 30, 2014 and Recent Highlights -- In September 2014, we announced the signing of a collaboration and...

2014-09-03 04:21:50

CRANBURY, N.J. and BUDAPEST, Hungary, Sept. 3, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: "Richter") announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the European Union, other European countries and additional selected countries. Richter is a European-based specialty...

2014-07-09 08:27:39

CRANBURY, N.J., July 9, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/910,422 (the '422 application). The application includes...

2014-06-27 08:24:54

CRANBURY, N.J., June 27, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it is joining the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes later today. Palatin was included on a preliminary list of...

2014-06-10 08:30:08

CRANBURY, N.J., June 10, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/311,824 (the '824 application). The application includes...

2014-05-20 08:34:24

Data show many women are not aware of hypoactive sexual desire disorder and often blame themselves for symptoms of low desire RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress and strains a woman's relationship with her...

2014-05-13 08:31:33

CRANBURY, N.J., May 13, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2014. Recent Highlights -- Pivotal Phase 3 clinical trials of bremelanotide for Female Sexual Dysfunction (FSD) are anticipated to start as early as...

2014-05-06 16:33:46

CRANBURY, N.J., May 6, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American Psychiatric Association (APA) 2014 Annual Meeting in New York, NY on Tuesday, May 6, 2014 at 2:30 PM ET. APA is the world's largest psychiatric organization. Bremelanotide is a first-in-class,...

2014-05-01 08:35:53

CRANBURY, N.J., May 1, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that a potential commercial partner has exercised its option for an exclusive license to bremelanotide for female sexual dysfunction (FSD) indications in the European Union and other European countries. The...

2014-04-29 08:35:16

CRANBURY, N.J., April 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28, 2014 at 3:45 PM local time. ACOG is the nation's leading group of...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'